189 related articles for article (PubMed ID: 34835449)
21. AIM2 Co-immunization with VP1 Is Associated with Increased Memory CD8 T Cells and Mounts Long Lasting Protection against Coxsackievirus B3 Challenge.
Yin L; Chai D; Yue Y; Dong C; Xiong S
Front Cell Infect Microbiol; 2017; 7():247. PubMed ID: 28642849
[TBL] [Abstract][Full Text] [Related]
22. Induction of mucosal HIV-specific B and T cell responses after oral immunization with live coxsackievirus B4 recombinants.
Gu R; Stagnar C; Zaichenko L; Ramsingh AI
Vaccine; 2012 May; 30(24):3666-74. PubMed ID: 22464964
[TBL] [Abstract][Full Text] [Related]
23. Strains of coxsackie virus B4 differed in their ability to induce acute pancreatitis and the responses were negatively correlated to glucose tolerance.
Hindersson M; Orn A; Harris RA; Frisk G
Arch Virol; 2004 Oct; 149(10):1985-2000. PubMed ID: 15669109
[TBL] [Abstract][Full Text] [Related]
24. Expression of an antigenic adenovirus epitope in a group B coxsackievirus.
Höfling K; Tracy S; Chapman N; Kim KS; Smith Leser J
J Virol; 2000 May; 74(10):4570-8. PubMed ID: 10775593
[TBL] [Abstract][Full Text] [Related]
25. A Coxsackievirus B vaccine protects against virus-induced diabetes in an experimental mouse model of type 1 diabetes.
Stone VM; Hankaniemi MM; Svedin E; Sioofy-Khojine A; Oikarinen S; Hyöty H; Laitinen OH; Hytönen VP; Flodström-Tullberg M
Diabetologia; 2018 Feb; 61(2):476-481. PubMed ID: 29151123
[TBL] [Abstract][Full Text] [Related]
26. Formalin treatment increases the stability and immunogenicity of coxsackievirus B1 VLP vaccine.
Hankaniemi MM; Stone VM; Andrejeff T; Heinimäki S; Sioofy-Khojine AB; Marjomäki V; Hyöty H; Blazevic V; Flodström-Tullberg M; Hytönen VP; Laitinen OH
Antiviral Res; 2019 Nov; 171():104595. PubMed ID: 31491431
[TBL] [Abstract][Full Text] [Related]
27. Persistent infection of human pancreatic cells with Coxsackievirus B4 is cured by fluoxetine.
Alidjinou EK; Sané F; Bertin A; Caloone D; Hober D
Antiviral Res; 2015 Apr; 116():51-4. PubMed ID: 25655448
[TBL] [Abstract][Full Text] [Related]
28. Persistence of Coxsackievirus B4 in pancreatic ductal-like cells results in cellular and viral changes.
Alidjinou EK; Engelmann I; Bossu J; Villenet C; Figeac M; Romond MB; Sané F; Hober D
Virulence; 2017 Oct; 8(7):1229-1244. PubMed ID: 28112573
[TBL] [Abstract][Full Text] [Related]
29. Characterization of the N-terminal part of the neutralizing antigenic site I of coxsackievirus B4 by mutation analysis of antigen chimeras.
McPhee F; Zell R; Reimann BY; Hofschneider PH; Kandolf R
Virus Res; 1994 Nov; 34(2):139-51. PubMed ID: 7531922
[TBL] [Abstract][Full Text] [Related]
30. Evidence for Anti-Viral Effects of Complete Freund's Adjuvant in the Mouse Model of Enterovirus Infection.
Gangaplara A; Massilamany C; Lasrado N; Steffen D; Reddy J
Vaccines (Basel); 2020 Jul; 8(3):. PubMed ID: 32645845
[TBL] [Abstract][Full Text] [Related]
31. Exogenous interleukin-12 protects against lethal infection with coxsackievirus B4.
Potvin DM; Metzger DW; Lee WT; Collins DN; Ramsingh AI
J Virol; 2003 Aug; 77(15):8272-9. PubMed ID: 12857896
[TBL] [Abstract][Full Text] [Related]
32. Vaccination with coxsackievirus B3 virus-like particles elicits humoral immune response and protects mice against myocarditis.
Zhang L; Parham NJ; Zhang F; Aasa-Chapman M; Gould EA; Zhang H
Vaccine; 2012 Mar; 30(13):2301-8. PubMed ID: 22306858
[TBL] [Abstract][Full Text] [Related]
33. Mucosal co-immunization with AIM2 enhances protective SIgA response and increases prophylactic efficacy of chitosan-DNA vaccine against coxsackievirus B3-induced myocarditis.
Chai D; Yue Y; Xu W; Dong C; Xiong S
Hum Vaccin Immunother; 2014; 10(5):1284-94. PubMed ID: 24614684
[TBL] [Abstract][Full Text] [Related]
34. A comparative study of the effect of UV and formalin inactivation on the stability and immunogenicity of a Coxsackievirus B1 vaccine.
Hankaniemi MM; Stone VM; Sioofy-Khojine AB; Heinimäki S; Marjomäki V; Hyöty H; Blazevic V; Laitinen OH; Flodström-Tullberg M; Hytönen VP
Vaccine; 2019 Sep; 37(40):5962-5971. PubMed ID: 31471148
[TBL] [Abstract][Full Text] [Related]
35. [A bivalent VP1 gene vaccine against Coxsackie virus B1/B3].
Wu X; Zhao T; Tian Y
Zhonghua Yi Xue Za Zhi; 2001 Apr; 81(8):480-4. PubMed ID: 11798923
[TBL] [Abstract][Full Text] [Related]
36. Viral myocarditis involves the generation of autoreactive T cells with multiple antigen specificities that localize in lymphoid and non-lymphoid organs in the mouse model of CVB3 infection.
Basavalingappa RH; Arumugam R; Lasrado N; Yalaka B; Massilamany C; Gangaplara A; Riethoven JJ; Xiang SH; Steffen D; Reddy J
Mol Immunol; 2020 Aug; 124():218-228. PubMed ID: 32615275
[TBL] [Abstract][Full Text] [Related]
37. Coxsackievirus B3-induced myocarditis. Characterization of stable attenuated variants that protect against infection with the cardiovirulent wild-type strain.
Zhang H; Morgan-Capner P; Latif N; Pandolfino YA; Fan W; Dunn MJ; Archard LC
Am J Pathol; 1997 Jun; 150(6):2197-207. PubMed ID: 9176409
[TBL] [Abstract][Full Text] [Related]
38. Expression of immunoregulatory cytokines by recombinant coxsackievirus B3 variants confers protection against virus-caused myocarditis.
Henke A; Zell R; Ehrlich G; Stelzner A
J Virol; 2001 Sep; 75(17):8187-94. PubMed ID: 11483764
[TBL] [Abstract][Full Text] [Related]
39. Cytolytic cross-reactive antibodies directed against the cardiac membrane and viral proteins in coxsackievirus B3 and B4 myocarditis. Characterization and pathogenetic relevance.
Maisch B; Bauer E; Cirsi M; Kochsiek K
Circulation; 1993 May; 87(5 Suppl):IV49-65. PubMed ID: 8485834
[TBL] [Abstract][Full Text] [Related]
40. Using recombinant coxsackievirus B3 to evaluate the induction and protective efficacy of CD8+ T cells during picornavirus infection.
Slifka MK; Pagarigan R; Mena I; Feuer R; Whitton JL
J Virol; 2001 Mar; 75(5):2377-87. PubMed ID: 11160741
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
